Tyra Biosciences
TYRA
46 hedge funds and large institutions have $387M invested in Tyra Biosciences in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 45 → 46 (+1)
1.61% more ownership
Funds ownership: 85.23% → 86.84% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
22% less capital invested
Capital invested by funds: $494M → $387M (-$108M)
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$7.59M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.37M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$7.11M |
| 4 |
SCM
Sio Capital Management
New York
|
+$1.32M |
| 5 |
JP Morgan Chase
New York
|
+$877K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$17.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.02M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$3.05M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.62M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.12M |
TYRA Hedge Fund Activity: Q1 2022 in Review
46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q1 2022, worth a combined $387M — down 22% from $494M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TYRA positions and 6 closed out — a net gain of 1 holder — while 12 added to existing stakes and 19 trimmed.
The largest buyer was Fairmount Funds Management, adding an estimated $7.59M. The largest seller was Frazier Management, exiting entirely with an estimated $17.6M sold.
- 46 institutional investors held Tyra Biosciences (TYRA) as of Q1 2022, up from 45 in Q4 2021.
- Funds reported $387M of Tyra Biosciences stock for Q1 2022, down 22% quarter-over-quarter.
- 7 funds opened new Tyra Biosciences positions in Q1 2022 and 6 closed out, a net change of +1 holder.
- The largest Tyra Biosciences buyer in Q1 2022 was Fairmount Funds Management, an estimated $7.59M added.
- The largest Tyra Biosciences seller in Q1 2022 was Frazier Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q1 2022.